Life Sciences Daily Summary: What Happened on October 15, 2026

FDA extends Anktiva to another form of bladder cancer

The FDA approved Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only bladder cancer that hasn’t invaded the muscle.1 The agency called it the first approved treatment specifically for this group.1

The decision drew on evidence from Anktiva’s earlier approval for bladder cancer involving carcinoma in situ, along with scientific similarities between the conditions.1 In the earlier-approval trial, 62% of 77 adults had a complete response. Of those responders, 40% maintained it for at least 24 months.1

Anktiva is delivered into the bladder through a catheter, initially once a week for six weeks. Further treatment depends on response.1 The FDA is finalizing guidance on using evidence from carcinoma-in-situ studies to support applications for papillary-only disease.1

OMass raises $310 million for endocrine and autoimmune programs

OMass Therapeutics raised $310 million in a Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings.3 The round brings the company’s total funding to about $475 million and is Europe’s second-largest private biotech financing of 2026, after Isomorphic’s $2.1 billion round in May.3

OMass said it will use most of the proceeds to advance OMS1620 through Phase 2 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.3 The company aims to block ACTH activity at the adrenal gland, lowering androgen production while allowing reduced glucocorticoid doses.3

OMass said the funding will also support early clinical development of an SLC15A4 inhibitor for lupus and other autoimmune diseases.3

Vanda pauses VQW-765 after Phase III anxiety trial misses endpoints

Vanda Pharmaceuticals paused clinical development of VQW-765 after a Phase III study missed its primary and key secondary endpoints.4

The study found no significant effect on acute social anxiety symptoms in the female subgroup or significant anxiety reduction across the full population.4 Vanda said it will analyze the full trial dataset while the program is paused.4

Vanda licensed VQW-765 from Novartis in 2014 and is not currently studying it for another condition.4

FDA starts work on a tailored rare-disease framework

The FDA launched an initiative to review how it develops and evaluates drugs and biologics for rare diseases, with the aim of accounting for differences in diseases, patient populations and feasible evidence.589

The agency plans to examine guidance, review practices, coordination among reviewers, patient input and manufacturing-quality review while retaining its safety and effectiveness standards.910

The FDA plans to begin gathering public input at an October 28 meeting, followed by roundtables and requests for information.89 Possible outcomes include new or revised guidance, regulatory changes, staff training or organizational adjustments. The agency hasn’t committed to a specific change.911

The FDA and the Department of Health and Human Services say about 5% of rare conditions have an approved treatment.511

MHRA adds clearer antidepressant risk information

The UK Medicines and Healthcare products Regulatory Agency is updating antidepressant safety information after patients and families raised concerns about suicidal thoughts and behavior, as well as sexual dysfunction that can persist after treatment ends.7

Medicine leaflets will get a boxed warning directing readers to information about suicidal thoughts and behavior. The regulator expects a patient card to accompany the medicines.7 Some leaflets will also use the term Post SSRI Sexual Dysfunction for symptoms that may continue after treatment stops.7

A separate safety leaflet for people starting or already taking antidepressants is due in 2027.7 MHRA chief safety officer Alison Cave advised patients to consult a healthcare professional before stopping medication.7

Iambic raises $150 million in IPO

Iambic raised $150 million in an initial public offering.6 Iambic said in regulatory filings that its AI drug-discovery approach could substantially change established methods.6